RecruitingPhase 2NCT07213973

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa

Sponsor

Incyte Corporation

Enrollment

40 participants

Start Date

Feb 2, 2026

Study Type

INTERVENTIONAL

Conditions

Hidradenitis Suppurativa (HS)

Summary

The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.

Eligibility

Min Age: 12 YearsMax Age: 17 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Povorcitinib for people with hidradenitis suppurativa (hs). The study is currently recruiting participants at 30 locations. People eligible for this study include aged 12 Years to 17 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPovorcitinib

Oral; Tablet

Locations(30)

University of Alabama At Birmingham

Birmingham, Alabama, United States

Medical Dermatology Specialists Phoenix

Phoenix, Arizona, United States

Saguaro Dermatology

Phoenix, Arizona, United States

Uconn Health

Farmington, Connecticut, United States

University of Miami Miller School of Medicine

Miami, Florida, United States

Skin Research of South Florida, Llc

Miami, Florida, United States

Trueblue Clinical Research

Tampa, Florida, United States

Advanced Medical Research Pc

Sandy Springs, Georgia, United States

Endeavor Health Medical Group

Skokie, Illinois, United States

Dermatology Skin Cancer Center Leawood

Leawood, Kansas, United States

Equity Medical

Bowling Green, Kentucky, United States

Johns Hopkins Univ Schl of Medicine

Baltimore, Maryland, United States

Skin Oasis Dermatology

Gambrills, Maryland, United States

Boston Childrens Hospital

Boston, Massachusetts, United States

Oakland Hills Dermatology Pc

Auburn Hills, Michigan, United States

Wayne State University Physician Group Dermatology

Detroit, Michigan, United States

Revival Research Institute, Llc Troy

Troy, Michigan, United States

University of Missouri Kansas City

Kansas City, Missouri, United States

Washington University

St Louis, Missouri, United States

Boeson Research Missoula 2825 Fort Missoula Rd

Missoula, Montana, United States

University of New Mexico Hospital

Albuquerque, New Mexico, United States

Geisinger Medical Center

Danville, Pennsylvania, United States

Bellaire Dermatology Associates Bda

Bellaire, Texas, United States

Texas Dermatology Research Center

Dallas, Texas, United States

3A Research Llc West Location

El Paso, Texas, United States

Jordan Valley Dermatology Center

South Jordan, Utah, United States

Dermcare Clinic

Mississauga, Ontario, Canada

York Dermatology Center

Richmond Hill, Ontario, Canada

The Hospital For Sick Children

Toronto, Ontario, Canada

Skincare Studio Dermatology Centre

St. John's, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07213973

Related Trials

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498318 locations

Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa

NCT074895737 locations

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

NCT07783542

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa

NCT06932003

Exploration of Brain Functional Networks in Patients With Hidradenitis Suppurativa Using fMRI

NCT07755670